News Story: Full Text
Sponsored By
Gleolan for brain tumors
Please Click On The Above Banner For More Details
Braintumor Website

 

Phase I/II Clinical Study of ONC201 Begins in Japan

Al's Comment:

 We are supporting their USA program!  This is an experimental treatment for Brain tumors with the H3K27M mutation, such as Diffuse Midline Glioma, and DIPG.


Posted on: 04/02/2020

 Phase I/II Clinical Study of ONC201 Begins in Japan

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740